// App-Quantinova.ai

TPS177 : Phase II trial of bolus 5-FU/l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant unresectable gastric cancer (HGCSG1502).

Researchers

Presenter

  • Tetsuhito Muranaka

Principal Investigators

  • Kentaro Sawada

  • Yasuyuki Kawamoto

  • Hiroshi Nakatsumi

  • Masayoshi Dazai

  • Hideyuki Hayashi

  • Michio Nakamura

  • Atsushi Ishiguro

  • Susumu Sogabe

  • Yoshimitsu Kobayashi

  • Takuto Miyagishima

  • Ichiro Iwanaga

  • Miki Tateyama

  • Kazuteru Hatanaka

  • Takashi Kato

  • Naoya Sakamoto

  • Yuh Sakata

  • Yoshito Komatsu

Medical Centers

  • Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Japan, Sapporo, Japan

  • Hokkaido University Hospital, Sapporo, Japan

  • Department of Gastroenterology and Hepatology, Hokkaido University Hospital, japan, Sapporo, Japan

  • Department of Gastroenterology, Sapporo Medical Center NTT EC, Sapporo, Japan

  • Department of Gastroenterology, Abashiri-Kosei General Hospital, Abashiri, Japan

  • Department of Medical Oncology,Osaki Citizen Hospital, Osaki-Shi, Japan

  • Department of Medical Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan

  • Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan

  • Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan

  • Department of Gastroenterology, Japanese Red Cross Kitami Hospital, Kitami, Japan

  • Department of Medical Oncology, Tomakomai Nisshou Hospital, Tomakomai, Japan

  • Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan

  • Department of Internal Medicine, Hokkaido Gastroenterology Hospital, Sapporo, Japan

  • Misawa City Hospital, Misawa, Japan

  • Hokkaido University Hospital Cancer Center, Sapporo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastric Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Fluorouracil

  • Adrucil injection

  • Capecitabine

  • Oxaliplatin

  • Ramucirumab

  • Paclitaxel

  • Docetaxel

  • Cisplatin

Outcome

  • N/A

Study Design

  • Single Arm

  • Prospective

Phase

  • II

Study Id's

  • JCOG9912

  • UMIN000018882

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved